Biomea Fusion Reports FY 2025 Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy BMEA?
Source: seekingalpha
- Earnings Highlights: Biomea Fusion reported a FY 2025 GAAP EPS of -$1.18, beating expectations by $0.36, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Cash Position: As of December 31, 2025, the company had $56.2 million in cash, cash equivalents, and restricted cash, down from $58.6 million as of December 31, 2024, reflecting challenges in cash management.
- Market Engagement: Biomea Fusion presented at several key conferences in 2026, including the International Conference on Advanced Technologies & Treatments for Diabetes, showcasing its active participation and technology promotion within the industry.
- Investor Sentiment: Seeking Alpha's Quant Rating on Biomea Fusion indicates a cautious market outlook regarding its future performance, prompting investors to monitor the company's progress in R&D and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMEA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMEA
Wall Street analysts forecast BMEA stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 1.540
Low
4.00
Averages
7.75
High
12.00
Current: 1.540
Low
4.00
Averages
7.75
High
12.00
About BMEA
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biomea Fusion Completes Chronic Toxicology Studies for Icovamenib
- Successful Toxicology Studies: Biomea Fusion has successfully completed chronic toxicology studies for icovamenib, providing nonclinical support for chronic clinical dosing beyond the 12-week duration, demonstrating a favorable safety profile that is expected to facilitate further clinical trial advancements.
- Clinical Trial Progress: In the Phase II COVALENT-112 trial for type 1 diabetes, icovamenib showed a 52% increase in mean C-peptide AUC at 52 weeks compared to baseline, supporting its efficacy as a novel therapeutic approach that could significantly alter existing treatment paradigms.
- New Trial Initiation: Biomea plans to initiate a Phase II clinical trial for recently diagnosed type 1 diabetes patients at four U.S. academic centers to evaluate the extended dosing of icovamenib, with the trial expected to start in the second half of 2026.
- Improved Financial Position: As of March 31, 2026, Biomea reported cash and cash equivalents of $45.1 million, a decrease from the previous year, but with R&D expenses significantly reduced to $9.1 million, indicating effective cost management strategies.
See More
Biomea Fusion Q1 Earnings Beat Expectations
- Earnings Highlights: Biomea Fusion reported a Q1 GAAP EPS of -$0.17, beating market expectations by $0.07, indicating an improvement in financial performance that may bolster investor confidence.
- Cash Position: As of March 31, 2026, the company had $45.1 million in cash, cash equivalents, and restricted cash, ensuring sufficient funding for ongoing R&D and operations, which supports its clinical trials and product development.
- Clinical Trial Progress: Biomea Fusion achieved positive top-line results in the COVALENT-112 trial for Icovamenib, demonstrating the drug's potential in treating Type 1 diabetes, which could enhance the company's competitive position in the market.
- Market Sentiment: Seeking Alpha's quant rating on Biomea Fusion reflects a positive outlook on its future developments, potentially attracting more investor interest in the company's growth prospects.
See More
Biomea Fusion Announces Late-Breaking Presentations at ADA Conference
- Poster Presentation Selection: Biomea Fusion announced that three abstracts on icovamenib have been selected for late-breaking poster presentations at the American Diabetes Association's 86th Scientific Sessions, taking place from June 5 to 8, 2026, in New Orleans, showcasing the company's influence in diabetes research.
- Research Highlights: The presentations will include data on icovamenib's application in both type 1 and type 2 diabetes, emphasizing its potential to improve beta cell function and support metabolic health, which could provide new treatment options for diabetes patients.
- Clinical Development Stage: Icovamenib is currently in Phase 2 clinical development as an orally administered small molecule targeting pathways associated with insulin secretion and glycemic control, showing potential to restore beta cell mass and function, which may change the landscape of diabetes treatment.
- Company Mission and Vision: Biomea Fusion focuses on developing oral small molecule therapies for diabetes and obesity, aiming to deliver transformative treatments for metabolic disorders affecting nearly half of Americans and one-fifth of the global population, reflecting the company's strategic importance in public health.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 1 Diabetes Trial
- Clinical Trial Results: Biomea Fusion's Phase 2 COVALENT-112 trial showed that Icovamenib 200 mg once daily led to a 52% increase in mean C-peptide AUC at 12 weeks in patients diagnosed with type 1 diabetes within the last 0-3 years, indicating significant improvement in endogenous insulin secretion.
- Long-Term Efficacy: In patients with a longer disease duration of 3-15 years, C-peptide levels were generally preserved through Week 52, with only a modest decline of approximately 7%, demonstrating the drug's effectiveness and tolerability over an extended period.
- Safety Profile: Throughout the 52-week observation period, Icovamenib was generally well tolerated, with no new or unexpected safety signals identified, enhancing its potential as a diabetes treatment option.
- Future Research Plans: Biomea plans to initiate a new Phase 2 trial in the second half of 2026 to evaluate the effects of extended dosing of 200 mg on C-peptide levels and the potential benefits of adding an immunosuppressive agent to improve clinical outcomes.
See More
Biomea Fusion Reports Positive Results for Diabetes Treatment
- Significant C-Peptide Increase: In patients diagnosed with diabetes within 0-3 years receiving 200 mg of icovamenib, a 52% increase in mean C-peptide AUC was observed at Week 12, indicating a substantial therapeutic effect and potential for improving insulin secretion.
- Durability of Effect: The 200 mg group maintained a mean C-peptide AUC with only a 7% decline from baseline at Week 52, suggesting the treatment's lasting impact, which could offer new hope for diabetes patients.
- Good Safety Profile: Icovamenib was generally well tolerated throughout the 52-week observation period, with no new safety signals identified, highlighting its potential as a short-course oral therapy that could transform diabetes treatment.
- Future Research Plans: Biomea is planning a Phase 2 trial at four U.S. academic centers to evaluate the effects of extended dosing at 200 mg, further validating icovamenib's application in diabetes treatment.
See More
Biomea Fusion Completes Chronic Toxicology Studies for Icovamenib
- Successful Toxicology Studies: Biomea Fusion has successfully completed chronic toxicology studies for icovamenib, providing nonclinical support for chronic clinical dosing beyond the 12-week duration, demonstrating a favorable safety profile that is expected to facilitate further clinical trial advancements.
- Clinical Trial Progress: In the Phase II COVALENT-112 trial for type 1 diabetes, icovamenib showed a 52% increase in mean C-peptide AUC at 52 weeks compared to baseline, supporting its efficacy as a novel therapeutic approach that could significantly alter existing treatment paradigms.
- New Trial Initiation: Biomea plans to initiate a Phase II clinical trial for recently diagnosed type 1 diabetes patients at four U.S. academic centers to evaluate the extended dosing of icovamenib, with the trial expected to start in the second half of 2026.
- Improved Financial Position: As of March 31, 2026, Biomea reported cash and cash equivalents of $45.1 million, a decrease from the previous year, but with R&D expenses significantly reduced to $9.1 million, indicating effective cost management strategies.
See More
Biomea Fusion Q1 Earnings Beat Expectations
- Earnings Highlights: Biomea Fusion reported a Q1 GAAP EPS of -$0.17, beating market expectations by $0.07, indicating an improvement in financial performance that may bolster investor confidence.
- Cash Position: As of March 31, 2026, the company had $45.1 million in cash, cash equivalents, and restricted cash, ensuring sufficient funding for ongoing R&D and operations, which supports its clinical trials and product development.
- Clinical Trial Progress: Biomea Fusion achieved positive top-line results in the COVALENT-112 trial for Icovamenib, demonstrating the drug's potential in treating Type 1 diabetes, which could enhance the company's competitive position in the market.
- Market Sentiment: Seeking Alpha's quant rating on Biomea Fusion reflects a positive outlook on its future developments, potentially attracting more investor interest in the company's growth prospects.
See More
Biomea Fusion Announces Late-Breaking Presentations at ADA Conference
- Poster Presentation Selection: Biomea Fusion announced that three abstracts on icovamenib have been selected for late-breaking poster presentations at the American Diabetes Association's 86th Scientific Sessions, taking place from June 5 to 8, 2026, in New Orleans, showcasing the company's influence in diabetes research.
- Research Highlights: The presentations will include data on icovamenib's application in both type 1 and type 2 diabetes, emphasizing its potential to improve beta cell function and support metabolic health, which could provide new treatment options for diabetes patients.
- Clinical Development Stage: Icovamenib is currently in Phase 2 clinical development as an orally administered small molecule targeting pathways associated with insulin secretion and glycemic control, showing potential to restore beta cell mass and function, which may change the landscape of diabetes treatment.
- Company Mission and Vision: Biomea Fusion focuses on developing oral small molecule therapies for diabetes and obesity, aiming to deliver transformative treatments for metabolic disorders affecting nearly half of Americans and one-fifth of the global population, reflecting the company's strategic importance in public health.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 1 Diabetes Trial
- Clinical Trial Results: Biomea Fusion's Phase 2 COVALENT-112 trial showed that Icovamenib 200 mg once daily led to a 52% increase in mean C-peptide AUC at 12 weeks in patients diagnosed with type 1 diabetes within the last 0-3 years, indicating significant improvement in endogenous insulin secretion.
- Long-Term Efficacy: In patients with a longer disease duration of 3-15 years, C-peptide levels were generally preserved through Week 52, with only a modest decline of approximately 7%, demonstrating the drug's effectiveness and tolerability over an extended period.
- Safety Profile: Throughout the 52-week observation period, Icovamenib was generally well tolerated, with no new or unexpected safety signals identified, enhancing its potential as a diabetes treatment option.
- Future Research Plans: Biomea plans to initiate a new Phase 2 trial in the second half of 2026 to evaluate the effects of extended dosing of 200 mg on C-peptide levels and the potential benefits of adding an immunosuppressive agent to improve clinical outcomes.
See More
Biomea Fusion Reports Positive Results for Diabetes Treatment
- Significant C-Peptide Increase: In patients diagnosed with diabetes within 0-3 years receiving 200 mg of icovamenib, a 52% increase in mean C-peptide AUC was observed at Week 12, indicating a substantial therapeutic effect and potential for improving insulin secretion.
- Durability of Effect: The 200 mg group maintained a mean C-peptide AUC with only a 7% decline from baseline at Week 52, suggesting the treatment's lasting impact, which could offer new hope for diabetes patients.
- Good Safety Profile: Icovamenib was generally well tolerated throughout the 52-week observation period, with no new safety signals identified, highlighting its potential as a short-course oral therapy that could transform diabetes treatment.
- Future Research Plans: Biomea is planning a Phase 2 trial at four U.S. academic centers to evaluate the effects of extended dosing at 200 mg, further validating icovamenib's application in diabetes treatment.
See More
